Lipid Lowering Therapy, an essential aspect of cardiovascular care, is designed to address and control elevated cholesterol and triglyceride levels within the bloodstream. By employing various medications like statins, fibrates, or cholesterol absorption inhibitors, this therapeutic approach aims to bring about a significant reduction in lipid levels, thereby reducing the risk of cardiovascular diseases, including heart attacks and strokes. The significance of Lipid Lowering Therapy lies in its ability to curtail one of the primary risk factors associated with cardiovascular complications. Regular monitoring of lipid levels and the implementation of personalized treatment plans are key elements in ensuring the effectiveness of Lipid Lowering Therapy. Healthcare professionals tailor interventions based on individual patient profiles, considering factors such as age, medical history, and existing conditions. This personalized approach enhances the precision and success of the therapy, emphasizing its role in holistic cardiovascular management.
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical Center, United States
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Preservation of Skeletal Muscle Mass During GLP 1 Receptor Agonist Mediated Weight Loss Clinical Determinants Risk Stratification and Evidence Based Mitigation Strategies
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : A Unique Case of Infective Endocarditis: Staphylococcus lugdunensis Infective Endocarditis Presenting as Embolic Occipital Stroke Due to Posterior Mitral Leaflet Perforation
Nuha Hasnain, Royal Preston Hospital, United Kingdom
Title : New recommendations for the prevention of sudden cardiac death in athletes and recreational sports
Sekib Sokolovic, ASA Hospital Sarajevo, Bosnia and Herzegowina
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation